Charles River Laboratories International, Inc.· CRL
🇺🇸 US · LargeSP500NYSE
- Price
- $234.12
- Day
- +1.41%
- Mkt Cap
- $11.28B
- 52W Range
- $144.26 – $242.73
- Volume
- 870.0K
- Beta
- 1.38
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
California State Teachers Retirement System lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 21.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,972 shares of the medical research company's stock after
Read full article
Avidity Partners Management LP bought a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the medical research company's stock, valued at approximately $1,670,000. Several other hedge funds
Read full article
CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.
Read full article
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Epoch Investment Partners Inc. reduced its holdings in Charles River Laboratories International, Inc. (NYSE: CRL) by 77.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,308 shares of the medical research company's stock after selling 21,131 shares during the quarter. Epoch
Read full article
On July 23, 2026, Charles River Laboratories International Inc (CRL) shares rose 4.8% to a current price of $229.29. This movement marks a significant increase
Read full article
Fifth Third Bancorp grew its stake in shares of Charles River Laboratories International, Inc. (NYSE: CRL) by 51.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,733 shares of the medical research company's stock after acquiring an additional
Read full article
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
Read full article
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read full article